Real-world outcomes of trastuzumab deruxtecan in patients with HER2+ metastatic breast cancer: Turkish oncology group multicenter study - PubMed
6 hours ago
- #trastuzumab deruxtecan
- #HER2+ metastatic breast cancer
- #real-world evidence
- Trastuzumab deruxtecan (T-DXd) shows significant improvements in survival for HER2+ metastatic breast cancer (mBC) patients.
- Real-world study in Türkiye with 269 patients across 27 oncology centers.
- Median real-world progression-free survival (rwPFS) was 17.9 months, and overall survival (rwOS) was 35.7 months.
- Objective response rate was 71.4%, and disease control rate was 95.2%.
- Patients treated with T-DXd in the second line had longer rwPFS compared to later lines (p < 0.001).
- Treatment-related adverse events (AEs) occurred in 68.4% of patients, with interstitial lung disease reported in 7.8%.
- T-DXd demonstrated robust antitumor activity and manageable safety in a lower-middle-income country (LMIC) setting.
- Findings support the broader clinical applicability of T-DXd beyond clinical trials.